Company intelligence / Profile preview

Montdorex

Ownership: Private
Employees: ~1
Development stage: Preclinical

Overview

Montdorex is developing proprietary small molecule inhibitors of the endo-exonuclease enzyme, aiming to block DNA repair in cancer cells and provide non-cytotoxic anti-inflammatory agents. The company’s lead compounds are at an early stage, with preclinical data supporting their potential efficacy in oncology and inflammation. Clinical results have not yet been published; the company presented preclinical findings at AACR 2024.

Therapeutic areas: OncologyImmunology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

6 assets

MTDX203

Preclinical

5 more assets in the full pipeline.

Request access →

Partnerships

Academic collaboration with Mitacs for research on DNA repair proteins in cancer/inflammation

Beyond the preview

Go deeper on Montdorex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Montdorex.

Explore the full profile